Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology, Inc. (Nasdaq: UBX) announced its Investor and Analyst Day on October 12, 2022, focusing on the UBX1325 program, a novel Bcl-xL inhibitor targeting age-related eye diseases. Presentations will review Phase 2 BEHOLD data for diabetic macular edema (DME) and details of the Phase 2 ENVISION study for wet age-related macular degeneration (wAMD). Key topics include preliminary results showing significant vision improvement and upcoming milestones, such as full 24-week data from BEHOLD expected by year-end 2022 and ENVISION data anticipated in early 2023.
UNITY Biotechnology (Nasdaq: UBX) announced an Investor/Analyst Day on October 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET. The event will focus on age-related eye diseases and the potential treatment solution offered by its lead program, UBX1325.
Key discussions will include insights from Robert B. Bhisitkul, M.D., Ph.D., on the mechanism of action of UBX1325, along with recent clinical data from the BEHOLD study in Diabetic Macular Edema and the ENVISION study in wet Age-related Macular Degeneration.
UNITY Biotechnology has successfully completed patient enrollment for the ENVISION study, a Phase 2 clinical trial of its investigational compound UBX1325, aimed at treating wet age-related macular degeneration (AMD). A total of 51 patients were enrolled, exceeding targets by approximately 10%. The trial will compare UBX1325 against aflibercept over 24 weeks. Key data readouts are anticipated in Q1 and Q2 2023, with the company expressing optimism about UBX1325's potential to impact retinal disease treatments significantly.
UNITY Biotechnology, Inc. (Nasdaq: UBX) announced participation in key investor conferences this September, aimed at discussing their innovative therapeutics targeting aging diseases. The company will hold one-on-one meetings at the Citi 17th Annual BioPharma Conference from September 6-8 in Boston, and present a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 4 PM ET, available via webcast. UNITY focuses on treatments that eliminate senescent cells to benefit age-related ophthalmologic and neurologic conditions.
UNITY Biotechnology (Nasdaq: UBX) has priced an upsized public offering of 64,285,714 shares and warrants at $0.70 each, projected to raise approximately $45 million before expenses. The offering, closing on August 22, 2022, aims to finance ongoing clinical studies for UBX1325 and support general corporate needs. The warrants carry an exercise price of $0.85 and are valid for five years. This offering, managed by SVB Securities, Cantor, and Mizuho, follows a previously effective registration with the SEC.
UNITY Biotechnology announced a proposed underwritten public offering of $25 million of its common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. Proceeds will be used for ongoing clinical development of UBX1325, which includes BEHOLD and ENVISION studies, as well as general corporate purposes. The offering is subject to market conditions and other factors.
UNITY Biotechnology announced positive results from the Phase 2 BEHOLD study of UBX1325 for Diabetic Macular Edema, showing significant improvements in BCVA and CST with a favorable safety profile at 12 and 18 weeks. The company reported a cash position of $64.5 million as of June 30, 2022. Upcoming milestones include 24-week data from BEHOLD and 16-week data from the ENVISION study by year-end. Additionally, the Tie2/VEGF bispecific program has been advanced as a candidate, strengthening its pipeline.
UNITY Biotechnology reported significant results from the Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). After 18 weeks, subjects treated with a single injection of UBX1325 showed an improvement of +6.1 ETDRS letters in Best Corrected Visual Acuity (BCVA) compared to sham treatment (p = 0.0368). Additionally, UBX1325 stabilized retinal structure, evidenced by central subfield thickness (CST), while sham-treated patients experienced worsening conditions. The treatment demonstrated a favorable safety profile without serious complications, indicating the potential for UBX1325 to offer a long-lasting, disease-modifying alternative to current therapies.
UNITY Biotechnology (Nasdaq: UBX) will host an investor call on August 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET, featuring retinal expert Robert Bhisitkul, M.D., Ph.D. The discussion will center around its lead program, UBX1325, aimed at developing therapies targeting age-related diseases. The call will be accessible via their website, with a replay available shortly after. UNITY is focused on innovative therapeutics to combat aging diseases by eliminating senescent cells, with implications for ophthalmologic and neurologic conditions.
UNITY Biotechnology (NASDAQ: UBX) announced the presentation of 24-week clinical data from its Phase 1 study of UBX1325 at the ASRS 40th Annual Scientific Meeting, scheduled for July 14, 2022. UBX1325 is being developed for treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The investigational therapy has shown a favorable safety profile and improvements in visual acuity. The company aims to offer transformative outcomes for patients suffering from age-related ocular diseases.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
